Surrozen (NASDAQ:SRZN) Earns “Overweight” Rating from Cantor Fitzgerald

Surrozen (NASDAQ:SRZN)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They currently have a $40.00 price objective on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 53.02% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target (up from $32.00) on shares of Surrozen in a research note on Tuesday. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.00.

Surrozen Price Performance

Surrozen stock opened at $26.14 on Tuesday. Surrozen has a 12-month low of $5.90 and a 12-month high of $29.59. The company has a market capitalization of $224.02 million, a price-to-earnings ratio of -0.78 and a beta of 0.53. The firm’s fifty day moving average price is $24.34 and its 200 day moving average price is $18.81.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The firm had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%. Analysts forecast that Surrozen will post -8.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Tcg Crossover Gp Ii, Llc purchased 106,658 shares of Surrozen stock in a transaction dated Tuesday, March 24th. The shares were acquired at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the transaction, the insider owned 736,554 shares of the company’s stock, valued at approximately $18,185,518.26. This trade represents a 16.93% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Group Gp Lp Column III purchased 18,052 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the insider directly owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This represents a 1.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 330,291 shares of company stock valued at $7,478,785 in the last ninety days. Corporate insiders own 45.18% of the company’s stock.

Institutional Trading of Surrozen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ikarian Capital LLC acquired a new stake in Surrozen during the fourth quarter valued at approximately $1,487,000. Quadrature Capital Ltd acquired a new position in shares of Surrozen in the 4th quarter worth approximately $335,000. Millennium Management LLC increased its holdings in shares of Surrozen by 557.1% in the 4th quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock valued at $16,301,000 after acquiring an additional 611,497 shares during the last quarter. Eversept Partners LP increased its holdings in shares of Surrozen by 23.8% in the 4th quarter. Eversept Partners LP now owns 95,286 shares of the company’s stock valued at $2,153,000 after acquiring an additional 18,289 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its position in shares of Surrozen by 169.3% during the 4th quarter. Balyasny Asset Management L.P. now owns 190,489 shares of the company’s stock valued at $4,305,000 after acquiring an additional 119,757 shares in the last quarter. 66.57% of the stock is owned by institutional investors.

More Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Major shareholder TCG Crossover GP II purchased 106,658 shares on March 24 at an average $24.69, increasing its stake ~16.9% to 736,554 shares — a strong insider-buy signal that can support the stock. SEC Filing
• Positive Sentiment: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90, a smaller follow-on purchase that further signals insider confidence. SEC Filing
• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating with a $40 price target — a materially higher valuation that may attract buyers. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised its target to $36. Its analyst also issued a FY2030 EPS forecast (-$3.54), notably less negative than the broader consensus, signaling a more optimistic long-term view. TickerReport
• Neutral Sentiment: Short-interest reports for March show zero shorted shares and a 0.0 days-to-cover metric, but the entries include NaN and look inconsistent — treat this as unreliable data rather than a clear market signal.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.